英派药业-B（IMPACT THERAP-B）宣布，其核心候选药物塞纳帕利（Senaparib）已正式向欧洲委员会提交申请，寻求获得最终的上市授权决定。
这一关键步骤标志着该药物在欧盟地区的监管审查进入收官阶段，为潜在的市场准入铺平了道路。英派药业正积极推进塞纳帕利的国际化布局，此次提交是其在全球范围内拓展肿瘤治疗版图的重要里程碑。
目前，欧洲药品管理局（EMA）已对塞纳帕利完成科学评估，并将建议转呈至欧盟委员会。后者将据此做出具有法律约束力的最终审批决定，涵盖该药物在全部欧盟成员国的上市许可。业界普遍关注这一决定的最终走向，因为其结果不仅影响英派药业在欧洲的商业前景，也可能对全球PARP抑制剂市场竞争格局产生深远影响。
塞纳帕利作为一种高选择性PARP抑制剂，被视为英派药业最具潜力的在研资产之一。倘若获批，它将在欧洲市场与多款同类药物展开直接竞争，为卵巢癌等适应症患者提供新的治疗选项。随着最终审批期限的临近，市场的目光正聚焦于欧盟委员会的下一步动作。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.